Survodutide Peptide Vials
Acylated synthetic peptide acting at the glucagon and GLP-1 receptors, developed as a once-weekly agent · 10mg · boxes of 10 vials
Free delivery worldwide on orders over $1,000 (about £749)
Strength 1 option · price per box
Boxes
5% off at 10+ boxes (any mix, bac water not counted) · 15+ boxes or a strength we don’t list? Ask for a bulk price: WhatsApp · Email
Order on WhatsApp insteadPrefer email? Order by email
- No minimumBoxes of 10 vials
- Tracked shippingDispatched in 1–2 working days
- Batch COAFree on request
- Photographed firstBefore it ships
Purity guarantee and free replacement within 14 days if anything arrives damaged or wrong. How it works
We accept
- Bank transfer
PayPal- Crypto
Often ordered together
One box of each. Change strengths or quantities in the cart.
About Survodutide
What is Survodutide?
Overview
What is Survodutide?
Survodutide (BI 456906) is a synthetic peptide that activates two receptors: the glucagon receptor and the GLP-1 receptor. A fatty-acid side chain binds albumin and stretches its half-life to the once-weekly interval used in trials. The glucagon arm is what sets it apart: glucagon signalling acts directly on the liver and on energy expenditure, which is why survodutide has been studied in fatty-liver disease as well as obesity. Supplied as a lyophilised powder in sealed vials, boxed in tens, for laboratory research use only.
Survodutide at a glance
| Compound | Survodutide |
|---|---|
| Also known as | BI 456906, BI456906, Survodutide peptide, glucagon GLP-1 dual agonist |
| Classification | Acylated synthetic peptide acting at the glucagon and GLP-1 receptors, developed as a once-weekly agent |
| CAS number | 2805997-46-8 |
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4232 g/mol |
| Sequence | Glucagon-based peptide backbone carrying a fatty-acid side chain for albumin binding |
| PubChem CID | 168429725 |
| Purity | 99%+ by HPLC |
| Physical form | Lyophilised powder |
| Available strengths | 10 mg |
| Box quantity | 10 vials |
| Price from | $23.07 per vial ($230.71 per box) |
| Research status | Survodutide has published phase 2 trials in obesity and in metabolic dysfunction-associated steatohepatitis (MASH), and phase 3 results in obesity with fatty-liver disease were published in 2026. That puts it among the further-advanced compounds in this catalogue, with its trials in major journals. |
| Documentation | Batch-specific third-party COA |
These are catalogue target specifications, not batch results. The 99%+ purity figure is the specification we buy to. The authoritative figures for any particular box are the ones printed on that box’s Certificate of Analysis, which is lot-specific. What research grade actually means explains the difference. Terms such as HPLC purity and net peptide content are explained in the peptide glossary.
We make no “third-party verified” claim for a batch unless the matching report is supplied with it. Ask for the current COA for the lot in stock before you order — we will send it.
Prices for every strength
Pricing
Survodutide price per vial: 10mg
Survodutide starts at $23.07 per vial (£17.28), sold in boxes of 10 at $230.71. One box is the smallest order and there is no trade account or minimum spend. Larger volumes are negotiable.
| Strength | Per vial | Box of 10 |
|---|---|---|
| 10 mg | $23.07 £17.28 | $230.71 £172.85 |
Storage & reconstitution
Handling
How should Survodutide be stored and reconstituted?
Sealed vials tolerate ambient temperature in transit and keep at −20 °C beyond that. Reconstitute slowly down the vial wall, swirl rather than shake, then refrigerate at 2–8 °C and aliquot before freezing.
Why each of those matters, and what a freeze–thaw cycle actually costs: peptide handling and storage reference. How long a mixed vial keeps: reconstituted peptide shelf life.
What it is researched for
Research Context
What is Survodutide researched for?
Below is a plain-English summary of what published research has investigated, and what it has found. These are descriptions of research activity and published results. They are not claims about what Survodutide does, and nothing here is a statement that it is safe or effective for any purpose.
What the trials found
A 46-week phase 2 dose-finding trial in adults with obesity reported dose-dependent weight reduction against placebo, with gastrointestinal effects the most common adverse events. A separate phase 2 trial in MASH with liver fibrosis reported improvement in liver histology at 48 weeks. 12
Why the glucagon arm matters
Glucagon receptor activity acts on the liver directly and is linked to energy expenditure, which GLP-1 agonism alone does not provide. That is the rationale for studying survodutide in liver disease, now extended to a phase 3 trial in obesity with fatty-liver disease. 23
What is not established
Long-term outcome data is not yet published, and no regulator has approved survodutide for any use.
References
- 1Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol (2024). PMID 38330987
- 2A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med (2024). PMID 38847460
- 3Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med (2026). PMID 42252333
Links open the record on PubMed or PubMed Central. These are citations to published research, not claims about this product.
Laboratory uses
Applications
Where Survodutide is used in the laboratory
- Dual glucagon and GLP-1 receptor pharmacology, and how the balance between the two receptors shapes the response
- Liver research, including steatosis and fibrosis models, the main reason survodutide is studied apart from other incretin agonists
- Comparative work against the GLP-1, dual and triple agonists in this catalogue: semaglutide, tirzepatide and retatrutide
- Hepatic lipid metabolism and energy expenditure in rodent models
Batch COA
Verification
Does Survodutide come with a COA?
Yes — every box. Each batch of Survodutide is analysed by an independent third-party laboratory, and the certificate is tied to the batch number on the vial label.
Example COA. You receive the certificate matching your own batch.
Questions & answers
Questions
Survodutide questions, answered
How is survodutide different from tirzepatide and retatrutide?
All three act on more than one receptor, but not the same ones. Tirzepatide pairs GLP-1 with GIP; survodutide pairs GLP-1 with glucagon; retatrutide acts on all three. Survodutide is the only one of the three without GIP activity, which makes it the useful comparison when the question is what the glucagon arm adds.
Is survodutide approved?
No. Survodutide is an investigational compound in phase 3 trials and is not approved for any use in any country. The research material sold here is not a medicine and is not for human consumption.
How much does Survodutide cost?
Survodutide starts at $23.07 per vial, sold in boxes of 10 vials at $230.71 per box (about £172.85). 1 strength available: 10 mg. There is no minimum order.
Can I buy Survodutide 10mg vials in the UK?
Yes. Survodutide 10mg comes in boxes of 10 vials at $230.71 per box ($23.07 per vial, about £172.85 per box), sent tracked to UK addresses. There is no minimum order.
How is Survodutide shipped to the UK and USA?
Tracked to the UK, USA, EU and worldwide, in plain packaging, dispatched within 1–2 working days. Country-by-country estimates are on the shipping page.
Recently viewed
Catalogue
